Xenna Corporation Awarded National Contract as Approved Vendor for CalleX® Dry Heel Ointment on Federal Supply Schedule

Share Article

Carol J. Buck, CEO of Xenna Corporation (http://www.xenna.com) announced today that the company has been awarded a 5-year Federal Supply Schedule contract as vendor of its patented, diabetic-friendly CalleX Dry Heel Ointment.

Carol J. Buck, CEO of Xenna Corporation (http://www.xenna.com) announced today that the company has been awarded a 5-year Federal Supply Schedule contract as vendor of its patented CalleX Dry Heel Ointment. Diabetic-friendly CalleX Dry Heel Ointment has been used and sold by U.S. podiatrists since 2001, and has been marketed to consumers in the health and beauty sections of select U.S. retailers as a combination foot moisturizer/exfoliant since 2003.

Ms. Buck says, "We will be reaching out to the VA hospital podiatry departments and to VA clinics throughout the country, notifying them that CalleX Ointment is available on the Federal Supply Schedule and must be purchased directly from Xenna Corporation. We will also be working with the Indian Health Service and the federal prison system as well as the Department of Defense to provide CalleX Ointment."

A major consumer of healthcare services, the government operates over a thousand Departments of Veterans Affairs healthcare facilities across the country, in addition to Indian reservations and federal prisons - all consumers of products related to foot care.

Since Native Americans have a disproportionately high prevalence of diabetes, the fact that CalleX Ointment is diabetic-friendly and acid-free makes it a natural choice for those consumers. Buck believes the availability of CalleX Ointment will also come as good news to veterans, federal prisoners and the podiatrists and Nurse Practitioners who serve them.

CalleX Ointment is a patented cosmetic exfoliant and moisturizer for feet. CalleX softens and exfoliates dry, cracked feet with natural, fast-acting enzymes. Applied twice daily to dry or hardened areas of the foot, CalleX eliminates the need to use an abrasive device. After applying CalleX, a gentle rubbing action with a wet washcloth is sufficient to gradually exfoliate hardened, scaly skin, as it moisturizes dry or cracked areas. CalleX doesn't require scraping to leave heels and soles supple and smooth in two to four weeks.

Patented CalleX Ointment contains natural ingredients and is free of salicylic acid, urea, parabens, lanolin, preservatives and colorants. To ward off unpleasant foot odors, CalleX contains a small amount of natural peppermint oil. Regular use eliminates the need to scrape heels.

As part of its contract, Xenna has agreed to provide a prompt payment discount, quantity discounts and shipment to the 50 states, DC and Puerto Rico. Xenna also offers three-day expedited delivery and accepts government credit cards below and above the micro-purchase threshold for direct delivery orders.

Ms. Buck says, "Xenna is delighted and honored to have its diabetic-friendly CalleX Dry Heel Ointment awarded by the Department of Veterans Affairs and placed on the Federal Supply Schedule as of June 15, 2009."

Xenna Corporation values the environment and animal rights and formulates brands containing natural ingredients. Xenna products are made in the USA, are not tested on animals and do not contain animal byproducts.

Interested FSS government purchasing agents who wish to order CalleX Ointment or receive samples should contact Xenna Corporation for their FSS Price List by emailing info@xenna.com or calling their toll free number 800-368-6003 between the hours of 9AM and 5PM, Monday - Friday, Eastern Time.

For photos of toenails and feet before and after using Xenna products, go to http://www.callexointment.com.

Xenna is a certified woman-owned business, manufacturing in the USA. To contact them call 800-368-6003 (business hours, Mon. - Fri. Eastern Time). View their press page at http://www.xenna.com/info_pressreleases.html.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Carol J. Buck

800-368-6003
Email >